[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Northside Hospital, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":210},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,70,90,110,127,145,165,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100642651","phase-1-axatilimab--car-t-for-high-risk-lymphoma-100642651",false,"NCT07638982","Axatilimab + CAR-T for High-Risk Lymphoma","An Open-label, Phase I Trial, With an Expansion Cohort: Macrophage Conditioning to Synergize With CAR-T in High-risk Lymphoma (MAC-SHIFT)","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed large B-cell lymphoma\n* Presence of one or more high-risk features\n* Eligible to receive CAR-T according to the FDA label\n* Measurable disease by CT or PET\n* Adequate organ function unless related to lymphoma involvement:\n* Pulse oximetry ≥ 92% on room air\n* Ejection Fraction ≥ 40%\n* ALT\u002FAST \\\u003C 5x ULN\n* Bilirubin \\\u003C 3 x ULN\n* Calculated or measured creatinine Clearance ≥ 30 mL\u002Fmin\n\nExclusion Criteria:\n\n* KPS \\\u003C60\n* Second malignancy with a high metastatic potential within 3 years\n* Active CNS involvement. Treated CNS disease is allowed\n* Active HBV or HCV infection.\n* Active uncontrolled infections\n* Known HIV positive status\n* Allogeneic transplant within 100 days of enrollment\n* Active acute or chronic graft versus host disease\n* History of acute or chronic pancreatitis\n* History of myositis","ALL","8 Years",{"count":19,"type":20},29,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Axatilimab + CAR-T in High-Risk Lymphoma",[26,27,28,29,30,31],"Diffuse Large B Cell Lymphoma (DLBCL)","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","High-grade B-cell Lymphoma (HGBCL)","High-Grade B-Cell Lymphoma, Nos","PMBCL","Follicular Grade 3 Lymphoma","NOT_YET_RECRUITING","2026-06-05",{"date":35,"type":36},"2026-06-10","ACTUAL",{"date":38,"type":20},"2026-10-31",{"date":40,"type":20},"2029-12-31",{"name":42,"class":43},"Northside Hospital, Inc.","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100579784","phase-2-early-use-of-tacrolimus-in-hla-mismatched-haploidentical-allogeneic-hematopoietic-transplantation-with-post-transplant-cyclophosphamide-100579784","NCT06828796","Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide","Inclusion Criteria:\n\n* Availability of a 5\u002F10-8\u002F10 mismatched (HLA-A, B, DR) haploidentical related donor with a negative HLA cross-match in the host vs. graft direction and willing to provide peripheral blood stem cells\n* Karnofsky status \\>\u002F= 70%\n* Hematologic malignancy requiring allogeneic transplantation\n* First allogeneic transplant only. Prior autologous transplant is allowed.\n\nExclusion Criteria:\n\n* Poor cardiac function: LVEF \\\u003C40%\n* Poor pulmonary function: FEV1 and FVC \\\u003C50% predicted\n* Poor liver function: bilirubin \\>\u002F= 3mg\u002FdL (not due to hemolysis, Gilbert's or primary malignancy)\n* Poor renal function: Creatinine \\>\u002F= 2mg\u002FdL or creatinine clearance (calculated or measured creatinine clearance is permitted) \\\u003C40mL\u002Fmin based on Traditional Cockcroft-Gault formula\n* Women of childbearing potential who currently are pregnant or who are not practicing adequate contraception\n* Patients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow up","18 Years","80 Years",{"count":54,"type":20},20,[56],"PHASE2","To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process",[59,60],"Hematologic Disease and Disorders","Hematopoietic Cell Transplant","RECRUITING","2026-04-15",{"date":64,"type":36},"2026-04-16",{"date":66,"type":36},"2025-07-03",{"date":68,"type":20},"2028-06-30",{"name":42,"class":43},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":44},"100519645","phase-2-belumosudil-and-rituximab-for-primary-treatment-of-chronic-graft-versus-host-disease-100519645","NCT06046248","Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease","Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease","Inclusion Criteria:\n\n* First episode of systemic immunosuppression-requiring cGVHD, defined as classic cGVHD by the NIH consensus criteria (without features or characteristics of aGVHD)\n* Previously untreated, defined by having received \\\u003C10 days of corticosteroids or alternative systemic immunosuppressive agent started specifically for a new diagnosis of cGVHD\n* KPS \\>\u002F= 70%\n* Adequate hematologic function independent of platelet transfusion and G-CSF for at least 7 days prior to study entry: ANC \\>750 cells\u002Fmm3; Platelets \\>30,000 cells\u002Fmm#\n\nExclusion Criteria:\n\n* Late persistent or recurrent aGVHD\n* Active uncontrolled infection\n* History of HIV infection\n* Active HBV or HCV infection. Subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative PCR result before enrollment. Those who are PCR positive will be excluded.\n* Calculated CrCl \\\u003C30mL\u002Fmin\n* AST and\u002For ALT \\>5x ULN or direct bilirubin \\>3x ULN\n* Cardiac ejection fraction \\\u003C40% or history of uncontrolled cardiac arrhythmias\n* Has received more than one allogeneic transplant prior to the occurrence of cGVHD",{"count":78,"type":20},25,[56],"This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.",[82],"Chronic Graft Versus Host Disease",{"date":84,"type":36},"2026-04-20",{"date":86,"type":36},"2024-01-29",{"date":88,"type":20},"2027-12-31",{"name":42,"class":43},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":44},"100509102","phase-2-car-t-cell-therapy-in-patients-with-renal-dysfunction-100509102","NCT05909059","CAR T-cell Therapy in Patients With Renal Dysfunction","Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction","Inclusion Criteria:\n\n* Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma\n* Adequate bone marrow function to receive lymphodepleting chemotherapy\n* Renal function \\\u003C\u002F= 60mL\u002Fmin\u002F1.73m2\n* ECOG 0-2\n\nExclusion Criteria:\n\n* Relative CNS disorders\n* Active uncontrolled infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator\n* Use of therapeutic dose systemic corticosteroids (defined as \\>20mg\u002Fday prednisone or equivalent) within 72 hours of CAR-T administration",{"count":54,"type":20},[56],"This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.",[101,102,103],"Non-hodgkin Lymphoma,B Cell","Multiple Myeloma","Acute Lymphoblastic Leukemia, Adult",{"date":84,"type":36},{"date":106,"type":36},"2024-11-18",{"date":108,"type":20},"2027-08-31",{"name":42,"class":43},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100479176","phase-2-intrathecal-chemoprophylaxis-to-prevent-neurotoxicity-associated-with-blinatumomab-therapy-for-acute-lymphoblastic-leukemia-100479176","NCT05519579","Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Adults receiving first cycle of blinatumomab for relapse\u002Frefractory or MRD-positive B-cell Acute Lymphoblastic Leukemia\n* Adequate renal and hepatic function\n* Negative for HIV\n* Negative serum pregnancy test, if applicable\n* ECOG 0-2\n\nExclusion Criteria:\n\n* Active CNS involvement by ALL\n* Relative CNS disorders (seizure, paresis, aphasia, Cerebrovascular ischemia\u002Fhemorrhage, severe brain injury, dementia, Parkinson's, cerebellar disease, psychosis, coordination or movement disorder)\n* Contraindication to receive intrathecal methotrexate\n* Prior treatment with blinatumomab\n* Active malignancy other than ALL\n* Active infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator",{"count":54,"type":20},[56],"Changing the schedule of intrathecal chemotherapy to be given before and during blinatumomab will maintain the anti-leukemic effects of this drug while at the same time adding the benefit of limiting the neurotoxicity associated with cytokine release.",[120],"Acute Lymphoblastic Leukemia",{"date":84,"type":36},{"date":123,"type":36},"2023-06-30",{"date":125,"type":20},"2026-12-01",{"name":42,"class":43},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":44},"100471368","reduced-intensity-fludarabine-and-tbi-prior-to-haplo-identical-transplantation-100471368","NCT05417971","Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation","A Phase II Trial of Reduced Intensity Fludarabine and Total Body Irradiation-Based Conditioning Prior to Haplo-Identical Transplantation for Patients With Hematologic Malignancies","Inclusion Criteria:\n\n* Availability of 3\u002F6 - 5\u002F6 matched related donor with a negative HLA-cross match in the host vs. graft direction willing to donate peripheral blood stem cells\n* KPS \\>\u002F= 70%\n* Hematologic malignancy requiring allogeneic transplantation, with a predicted high risk of relapse following non-myeloablative, low intensity conditioning.\n\nExclusion Criteria:\n\n* Poor cardiac function (LVEF \\\u003C45%)\n* Poor pulmonary function (FEV, FVC, DLCO \\\u003C60%)\n* Poor liver function (bilirubin \\>\u002F= 2.5mg\u002FdL; AST or ALT \\>3xULN)\n* Poor renal function (creatinine clearance \\\u003C40mL\u002Fmin)\n* HIV-positive; active HepB or HepC\n* Uncontrolled infection\n* Pregnant female or not able to practice adequate contraception\n* Debilitating medical or psychiatric illness which would preclude their giving informed consent",{"count":54,"type":20},"OBSERVATIONAL","This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.",[138],"Hematologic Malignancy",{"date":64,"type":36},{"date":141,"type":36},"2022-08-29",{"date":143,"type":20},"2026-12-31",{"name":42,"class":43},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":21,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":44},"100380748","phase-2-gm-csf-with-post-transplant-cyclophosphamide-100380748","NCT04237623","GM-CSF With Post-Transplant Cyclophosphamide","Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post-Infusion of T-Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells and With Post Transplant Cyclophosphamide","Inclusion Criteria:\n\n* Availability of 5\u002F10 to 8\u002F10 matched related donor\n* KPS \\>\u002F= 70%\n* CML, AML, MDS, ALL, CLL, HD, NHL, MPS\u002FCMML, MM, any other hematologic condition deemed an eligible indication for allogeneic transplant by the treating center\n\nExclusion Criteria:\n\n* Poor cardiac, pulmonary, liver, and renal function\n* HIV-positive\n* Patients who have a debilitating medical or psychiatric illness that would preclude them from giving informed consent\n* History of severe or serious allergic reaction to human GM-CSF or yeast-derived products","78 Years",{"count":154,"type":20},38,[56],"Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.",[158],"Transplant-Related Hematologic Malignancy",{"date":64,"type":36},{"date":161,"type":36},"2020-05-18",{"date":163,"type":20},"2026-09-18",{"name":42,"class":43},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},"100272624","phase-2-haploidentical-bone-marrow-transplant-with-post-transplant-cyclophosphamide-for-patients-with-severe-aplastic-anemia-100272624","NCT02828592","Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia","A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor","Inclusion Criteria:\n\n* Availability of 3\u002F6 - 5\u002F6 matched (HLA-A, B, DR) related donor who must have negative HLA cross-match in the host vs. graft direction\n* Age \\\u003C= 65 years for previously treated and \\\u003C= 75 years for previously treated patients\n* KPS \\>= 70%\n* Aplastic Anemia that meets the following criteria:\n\nPeripheral Blood (must fulfill 2 of 3):\n\n* \\\u003C500 PMN\u002Fmm3\n* \\\u003C20,000 platelets\n* absolute reticulocyte count \\\u003C40,000\u002FmicroL\n\nBone Marrow (must be either):\n\n* markedly hypocellular (\\\u003C25% of normal cellularity)\n* moderately hypocellular with 70% non-myeloid precursors and patient meets peripheral blood criteria above\n\nExclusion Criteria:\n\n* poor cardiac function (LVEF \\\u003C40%)\n* poor pulmonary function (FEV1 \\& FVC \\\u003C50% predicted)\n* poor liver function (bili \\>= 2mg\u002FdL)\n* poor renal function (creatinine \\>= 2.0mg\u002FdL or creatinine clearance \\\u003C40mL\u002Fmin)\n* prior allogeneic transplant","1 Year","75 Years",{"count":54,"type":20},[56],"Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1\u002F3 of patients are cured, 1\u002F3 are dependent on long term immunosuppression, and the other 1\u002F3 relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic GVHD.",[178],"Severe Aplastic Anemia",[180],"SAA",{"date":84,"type":36},{"date":183,"type":36},"2016-09-09",{"date":185,"type":20},"2028-08-31",{"name":42,"class":43},2,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":44},"100632236","phase-1-axatilimab-combined-with-decitabinevenetoclax-for-the-treatment-of-tp53-mutated-aml-100632236","NCT07511062","Axatilimab Combined With Decitabine\u002FVenetoclax for the Treatment of TP53-mutated AML","Axatilimab Combined With Decitabine\u002FVenetoclax for the Treatment of TP53-mutated\u002FDeleted AML Patients","Inclusion Criteria:\n\n* MDS\u002FAML or AML with a TP53 mutation or deletion, defined as:\n* greater than or equal to 10% AND (one of the following):\n* presence of a TP53 mutation\n* presence of a TP53 deletion by FISH\n* positive TP53 staining on IHC of diagnostic bone marrow\n* Either untreated or first salvage (primary refractory or first relapse)\n\nExclusion Criteria:\n\n* KPS \\\u003C60\n* active uncontrolled infection\n* history of HIV or active HBV or HBC infection\n* currently active second malignancy\n* calculated CrCl \\\u003C40mL\u002Fmin\n* AST and\u002For ALT and\u002For direct bilirubin \\>3x ULN\n* cardiac ejection fraction \\\u003C40% or history of uncontrolled cardiac arrhythmias\n* history of acute or chronic pancreatitis, history of myositis\n* known leukemia involvement of CNS\n* hematopoietic stem cell transplantation within 3 months of treatment start and\u002For persistent non-hematologic toxicities of Grade 2+ related to the transplant\n* active acute or chronic GVHD requiring immunosuppressive treatment",{"count":196,"type":20},32,[23],"Axatilimab combined with Decitabine\u002FVenetoclax for the treatment of TP53-mutated\u002Fdeleted AML patients",[200,201],"Acute Myeloid Leukemia","TP53 Gene Mutation","2026-03-31",{"date":204,"type":36},"2026-04-06",{"date":206,"type":20},"2026-08-01",{"date":208,"type":20},"2030-08-01",{"name":42,"class":43},""]